Aron Y. Joon

ORCID: 0000-0003-2615-2179
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Brain Metastases and Treatment
  • Renal cell carcinoma treatment
  • Melanoma and MAPK Pathways
  • Metastasis and carcinoma case studies
  • Ferroptosis and cancer prognosis
  • Nanoplatforms for cancer theranostics
  • Bladder and Urothelial Cancer Treatments
  • Testicular diseases and treatments
  • Immunotherapy and Immune Responses
  • Cancer Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Liver Disease Diagnosis and Treatment
  • Click Chemistry and Applications
  • Cutaneous Melanoma Detection and Management
  • Molecular Biology Techniques and Applications
  • Prostate Cancer Treatment and Research
  • Renal and related cancers
  • CAR-T cell therapy research
  • BRCA gene mutations in cancer
  • Prostate Cancer Diagnosis and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Gut microbiota and health
  • Genetic factors in colorectal cancer

The University of Texas MD Anderson Cancer Center
2015-2025

AC Camargo Hospital
2018

The University of Texas Health Science Center at Houston
2014

Ludwig-Maximilians-Universität München
2014

National Institute on Aging
2014

St George's, University of London
2014

Fred Hutch Cancer Center
2014

The University of Texas Southwestern Medical Center
2014

Johns Hopkins University
2014

National Cancer Institute
2014

Gina M. Peloso Paul L. Auer Joshua C. Bis Arend Voorman Alanna C. Morrison and 94 more Nathan O. Stitziel Jennifer A. Brody Sumeet A. Khetarpal Jacy R. Crosby Myriam Fornage Aaron Isaacs Jóhanna Jakobsdóttir Mary F. Feitosa Gail Davies Jennifer E. Huffman Ani Manichaikul Brian R. Davis Kurt Lohman Aron Y. Joon Albert V. Smith Megan L. Grove Paolo Zanoni Valeska Redon Serkalem Demissie Kim Lawson Ulrike Peters Christopher Carlson Rebecca D. Jackson Kelli K. Ryckman Rachel H. Mackey Jennifer G. Robinson David S. Siscovick Pamela J. Schreiner Josyf C. Mychaleckyj James S. Pankow Albert Hofman André G. Uitterlinden Tamara B. Harris Kent D. Taylor Jeanette M. Stafford Lindsay M. Reynolds Riccardo E. Marioni Abbas Dehghan Oscar H. Franco Aniruddh P. Patel Yingchang Lu George Hindy Omri Gottesman Erwin P. Böttinger Olle Melander Marju Orho‐Melander Ruth J. F. Loos Stefano Duga Piera Angelica Merlini Martin Farrall Anuj Goel Rosanna Asselta Domenico Girelli Nicola Martinelli Svati H. Shah William E. Kraus Mingyao Li Daniel J. Rader Muredach P. Reilly Ruth McPherson Hugh Watkins Diego Ardissino Qunyuan Zhang Judy Wang Michael Y. Tsai Herman A. Taylor Adolfo Correa Michael Griswold Leslie A. Lange John M. Starr Igor Rudan Guðný Eiríksdóttir Lenore J. Launer José M. Ordovás Daniel Levy Yu Chen Alexander P. Reiner Caroline Hayward Ozren Polašek Ian J. Deary Ingrid B. Borecki Yongmei Liu Vilmundur Guðnason James G. Wilson Cornelia M. van Duijn Charles Kooperberg Stephen S. Rich Bruce M. Psaty Jerome I. Rotter Christopher J. O’Donnell Kenneth Rice Eric Boerwinkle Sekar Kathiresan L. Adrienne Cupples

10.1016/j.ajhg.2014.01.009 article EN publisher-specific-oa The American Journal of Human Genetics 2014-02-01

Abstract There is a critical need to improve our understanding of the pathogenesis melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor IHC. demonstrated heterogeneity immune infiltrates that correlated prior radiation post-craniotomy survival. Comparison identified significant immunosuppression enrichment oxidative...

10.1158/2159-8290.cd-18-1489 article EN Cancer Discovery 2019-02-20

Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for overdiagnosis low-risk underdiagnosis high-grade prostate cancer. To improve early-detection biopsy decisions, National Cancer Institute conducted prospective validation trial to assess diagnostic performance cancer 3 (PCA3) urinary assay detection among men screened with PSA.

10.1200/jco.2013.52.8505 article EN Journal of Clinical Oncology 2014-11-11

Importance Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection indolent cancers resulting from the poor specificity PSA for high-grade PCa (ie, grade group [GG] 2 or greater). Objective To develop a multiplex urinary panel validate its external performance relative to current guideline-endorsed biomarkers. Design, Setting, Participants RNA sequencing analysis 58 724 genes identified 54 markers...

10.1001/jamaoncol.2024.0455 article EN cc-by JAMA Oncology 2024-04-18

Constitutive activation of the epidermal growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly non-small cell lung carcinoma (NSCLC). Mutations identified EGFR predict sensitivity to EGFR-targeted therapy. Detection these mutations mainly based on tissue biopsy, which invasive, expensive, and time consuming.Noninvasive, real-time, inexpensive detection monitoring patients with NSCLC highly desirable.We developed a novel core technology, electric field-induced release...

10.1164/rccm.201406-1003oc article EN American Journal of Respiratory and Critical Care Medicine 2014-10-15

While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its applicability is currently limited by cost and bioinformatics requirements. We developed a method to accurately derive the predicted total (PTML) within individual tumors from small set of genes that can be used in next generation (NGS) panels. PTML was derived actual (ATML) 575 distinct melanoma lung cancer samples validated independent (n = 312) 217)...

10.1186/s12916-016-0705-4 article EN cc-by BMC Medicine 2016-10-24

Purpose: Sarcomatoid renal cell carcinoma (SRCC) ranks among the most aggressive clinicopathologic phenotypes of RCC. However, paucity high-quality, genome-wide molecular examinations SRCC has hindered our understanding this entity.Experimental Design: We interrogated mutational, copy number, and transcriptional characteristics compared these data with those nonsarcomatoid RCC (RCC). evaluated whole-exome sequencing, single-nucleotide polymorphism, RNA sequencing from patients (n = 65) 598)...

10.1158/1078-0432.ccr-17-1057 article EN cc-by Clinical Cancer Research 2017-07-15

Objective The aim of this study was to determine the association pancreatic steatosis with obesity, chronic pancreatitis (CP), and type 2 diabetes mellitus. Methods Patients (n = 118) were retrospectively identified categorized into no CP 60), mild 21), moderate 27), severe 10) groups based on clinical history magnetic resonance cholangiopancreatography using Cambridge classification as diagnostic standard. Visceral subcutaneous compartments manually segmented, fat tissue quantitatively...

10.1097/mpa.0000000000001252 article EN Pancreas 2019-02-12

Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation therapy can be constrained by immune-related adverse events (irAEs). Limited understanding irAE mechanisms hampers development approaches to mitigate their damage. To address this, we examined whether mice gained sensitivity anti-CTLA-4 (αCTLA-4)–mediated toxicity upon disruption gut homeostatic immunity. We found αCTLA-4 drove increased inflammation colonic tissue damage in with...

10.1084/jem.20221333 article EN cc-by-nc-sa The Journal of Experimental Medicine 2022-11-11

Background and Purpose— Genome-wide association studies have revealed multiple common variants associated with known risk factors for ischemic stroke (IS). However, their aggregate effect on is uncertain. We aimed to generate a multilocus genetic score (GRS) IS based genome-wide data from clinical-based samples establish its external validity in prospective population-based cohorts. Methods— Three thousand five hundred forty-eight clinic-based cases 6399 controls the Wellcome Trust Case...

10.1161/strokeaha.113.002938 article EN Stroke 2014-01-17

Autoimmune myocarditis is a rare but often fatal toxicity of checkpoint inhibitor immunotherapy. To improve the understanding this complication, we performed immune profiling on post-mortem tissue from patient with metastatic melanoma who had steroid-responsive hepatitis, steroid-refractory myocarditis, and shrinking lung metastases after ipilimumab treatment. Histological analysis heart demonstrated findings consistent giant cell (GCM). The infiltrate in was largely comprised CD4+ T cells,...

10.1080/2162402x.2017.1361097 article EN OncoImmunology 2017-08-08

Background Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity. Candidate gene and genome-wide studies have identified putative risk loci for overt cardiotoxicity heart failure, there has been no comprehensive assessment of genomic variation influencing the intermediate phenotype anthracycline-related changes in left ventricular (LV) function. The purpose this study was to identify genetic factors LV function after anthracycline chemotherapy....

10.1097/fpc.0000000000000284 article EN Pharmacogenetics and Genomics 2017-05-24

Hispanics are disproportionately affected by NAFLD, liver fibrosis, cirrhosis, and HCC. Preventive strategies noninvasive means to identify those in this population at high risk for urgently needed. We aimed characterize the gut microbiome signatures related biological functions associated with fibrosis environmental genetic factors affecting them.

10.1002/hep.32197 article EN Hepatology 2021-10-11

The gut microbiome composition varies across ethnicities and geographical locations, yet studies on diabetes-associated changes specific to high-risk Mexican Americans are lacking. Here, we aimed identify alterations associated with diabetes in this population, as well host genetic factors that may explain increased disease susceptibility ethnic group.

10.1128/msystems.00033-22 article EN mSystems 2022-04-28

Combined treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in only about 15% of patients BRAF inhibitor (BRAFi)-refractory metastatic melanoma contrast to the higher response rate observed BRAFi-naïve patients. Identifying correlates mechanisms resistance this population will facilitate management rational therapeutic development.To determine benefit from CombiDT therapy BRAFi-refractory melanoma.Single-center, single-arm, open-label phase 2 trial V600 resistant...

10.1001/jamaoncol.2016.0509 article EN JAMA Oncology 2016-04-28

BRAFV600 , NRAS, TP53, and BRAFNon-V600 are among the most common mutations detected in non-acral cutaneous melanoma patients. Although several studies have identified clinical pathological features associated with NRAS mutations, limited data available regarding correlates significance of TP53 mutations.This study analyzed patient demographics, primary tumor features, outcomes a large cohort patients who had undergone clinically indicated molecular testing (n = 926).The prevalence was 43%,...

10.1002/cncr.30463 article EN Cancer 2016-12-02

Melanoma mortality is driven by the formation and growth of distant metastases. Here, we interrogated role tumor oxidative phosphorylation (OXPHOS) in metastases melanoma. OXPHOS was most upregulated metabolic pathway primary tumors that formed RCAS-TVA mouse model spontaneous lung brain metastases, melanoma patients developed or other Knockout PGC1α melanocytes had no impact on formation, but markedly reduced incidence Genetic knockout a component electron transport chain complex I, NDUFS4,...

10.1101/2025.01.23.633049 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2025-01-24

Germ cell tumors of the testis (GCTs) provide an ideal tumor model to investigate cellular versus genetic origin cancers. In this single institutional study, we evaluated 38 patients with bilateral GCT, including that occurred simultaneously (synchronous) and those occurring at different times (metachronous). For nine these patients, DNA was isolated from right left GCT determine genomic epigenetic differences between tissues using whole-exome sequencing (WES) reduced representation...

10.3390/cells14090658 article EN cc-by Cells 2025-04-30

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This particularly relevant a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns heterogeneity cancer dormancy subsequent second malignancies (subsequent malignant neoplasms (SMNs)). From our registry database, we identified 655 testicular (TGCT) patients who developed SMNs between January 1990 September 2018. Of 113 solid organ SMNs, 42 had sufficient...

10.3390/cancers12123755 article EN Cancers 2020-12-14

Initiatives such as The Cancer Genome Atlas (TCGA) and International Consortium (ICGC) have generated high-quality, multi-platform molecular data from thousands of frozen tumor samples. While these initiatives provided invaluable insight into cancer biology, a tremendous potential resource remains largely untapped in formalin-fixed, paraffin-embedded (FFPE) samples that are more readily available, but which can present technical challenges due to crosslinking fragile molecules RNA.We...

10.1200/po.17.00259 article EN JCO Precision Oncology 2018-06-14

Background: Bone is the most common site of metastasis breast cancer. Biological mechanisms to bone may be different from non-bone sites, and identification distinct signaling pathways somatic mutations provide insights on biology rational targets for treatment prevention metastasis. The aims this study were compare contrast mutations, clinicopathologic characteristics, survival in cancer patients with bone-only versus sites first Methods: Primary tumor samples collected before 389 untreated...

10.7150/jca.26825 article EN cc-by-nc Journal of Cancer 2018-01-01

Recently, we showed that melanoma brain metastases (MBMs) are characterized by increased utilization of the oxidative phosphorylation (OXPHOS) metabolic pathway compared to extracranial (ECMs). MBM growth was inhibited a potent direct OXPHOS inhibitor, but observed toxicities support need identify alternative therapeutic strategies. Thus, explored features associated with improve our understanding pathogenesis and potential vulnerabilities MBMs.We applied an gene signature cohort surgically...

10.1093/noajnl/vdaa177 article EN cc-by Neuro-Oncology Advances 2021-01-01

Background Clustering of breast and colorectal cancer has been observed within some families cannot be explained by chance or known high-risk mutations in major susceptibility genes. Potential shared genetic between cancer, not high-penetrance genes, postulated. We hypothesized that yet undiscovered variants predispose to a breast-colorectal phenotype. Methods To identify associated with phenotype, we analyzed genome-wide association study (GWAS) data from cases controls met the following...

10.1371/journal.pone.0196245 article EN cc-by PLoS ONE 2018-04-26
Coming Soon ...